146
Participants
Start Date
October 7, 2021
Primary Completion Date
October 11, 2023
Study Completion Date
May 26, 2024
Pembrolizumab
"200 mg IV administered on Day 1 of each 3-week cycle for 3 cycles during pembrolizumab monotherapy.~400 mg IV administered on Day 1 of each 6-week cycle for 4 cycles as pembrolizumab consolidation."
Doxorubicin
"25 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles in all participants after PET scan 2 and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).~35 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive, \<60 years of age)."
Vinblastine
6 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles after PET scan 2 (all participants) and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).
Dacarbazine
375 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles after PET scan 2 (all participants) and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).
Bleomycin
10 units/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 8 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Etoposide
200 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Days 1-3 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Cyclophosphamide
1250 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Vincristine
1.4 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 8 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Procarbazine
100 mg/m\^2 orally (PO) administered as part of escBEACOPP chemotherapy on Days 1-7 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Prednisone
40 mg/m\^2 PO administered as part of escBEACOPP chemotherapy on Days 1-14 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).
Liverpool Hospital-Haematology ( Site 0906), Liverpool
Peter MacCallum Cancer Centre ( Site 0905), Melbourne
Monash Health-Haematology Research ( Site 0908), Clayton
Mater Misericordiae Limited ( Site 0904), Brisbane
Princess Alexandra Hospital-Division of Cancer Services Trials Unit ( Site 0907), Woolloongabba
Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand ( Site 1504), Dijon
Azienda Ospedaliera Spedali Civili di Brescia-Hemathology ( Site 1801), Brescia
Hospital Universitario 12 de Octubre ( Site 1032), Madrid
CHU Bordeaux Haut-Leveque ( Site 1505), Pessac
Vehbi Koc Vakfi - Amerikan Hastanesi ( Site 5001), Istanbul
Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou-haematology ( Site 1502), Rennes
University of Tennessee Medical Center-Cancer Institute ( Site 0006), Knoxville
Policlinico S. Orsola- Malpighi-Istituto di Ematologia L. e A. Seragnoli ( Site 1800), Bologna
Northwestern Memorial Hospital ( Site 0002), Chicago
centre hospitalier lyon sud-Service Hématologie ( Site 1501), Pierre-Bénite
Texas Oncology-Plano East ( Site 0020), Plano
Centre de Lutte Contre le Cancer - Centre Henri Becquerel Normandie Rouen-Service d'Hématologie ( Si, Rouen
OptumCare Cancer Care-Research Department ( Site 0005), Las Vegas
St Joseph Heritage Healthcare-Oncology ( Site 0004), Fullerton
Stanford Cancer Center ( Site 0023), Palo Alto
Moscow City Clinical Hospital S.P. Botkin ( Site 0702), Moscow
First Pavlov State Medical University of Saint Petersburg-Raisa Gorbacheva Memorial Institut for Pe, Saint Petersburg
Almazov National Medical Research Centre ( Site 0704), Saint Petersburg
ZIV Medical Center ( Site 1908), Safed
Rambam Health Care Campus ( Site 1907), Haifa
Bnai Zion Medical Center-Hematology ( Site 1909), Haifa
Centro Investigación del Cáncer James Lind ( Site 1200), Temuco
Sheba Medical Center-Hemato Oncology ( Site 1904), Ramat Gan
Sourasky Medical Center ( Site 1905), Tel Aviv
FALP-UIDO ( Site 1202), Santiago
Clínica Alemana de Santiago ( Site 1206), Santiago
Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 1204), Santiago
Instituto Nacional del Cancer ( Site 1205), Chile
Hadassah Medical Center ( Site 1901), Jerusalem
Cross Cancer Institute ( Site 0207), Edmonton
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 0205), Greenfield Park
Jewish General Hospital ( Site 0200), Montreal
McGill University Health Centre ( Site 0209), Montreal
Hopital du Sacre-Coeur de Montreal ( Site 0206), Montreal
ASST Grande Ospedale Metropolitano Niguarda ( Site 1803), Milan
Dokuz Eylül Üniversitesi ( Site 5002), Balçova
Fondazione Policlinico Universitario Agostino Gemelli-ISTITUTO DI EMATOLOGIA ( Site 1804), Roma
Klinika Hematologii - Instytut Hematologii i Transfuzjologii-Klinika Hematologii ( Site 0402), Warsaw
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (, Warsaw
Szpital Wojewódzki w Opolu-Hematology Department ( Site 0401), Opole
Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 0403), Gdansk
Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 1031), L'Hospitalet Del Llobregat
Ankara University Hospital Cebeci-hematology ( Site 5000), Ankara
Merck Sharp & Dohme LLC
INDUSTRY